Teva halts sales of migraine patch on reports of burns, scars
Teva Pharmaceutical Industries has suspended sales of its migraine patch Zecuity following post-marketing reports of burns and scars in patients.
Read More
Tag: Zecuity
- European life sciences coalition launched to boost investment ecosystem
- 99mtc‑maraciclatide granted fast track status for ILD imaging
- Bioxytran reports rapid viral clearance in phase 2 trial
- Thx Pharma and Biocodex sign rare disease licensing deal
- AstraZeneca bladder cancer therapy wins NICE backing
